ALY-301
Cold Urticaria / Chronic Inducible Urticaria (CIndU)
Phase 1/1bActive
Key Facts
Indication
Cold Urticaria / Chronic Inducible Urticaria (CIndU)
Phase
Phase 1/1b
Status
Active
Company
About Alys Pharmaceuticals
Alys Pharmaceuticals is a newly formed, privately held biotech company based in Boston, focused exclusively on immuno-dermatology. It was created through the aggregation of six Medicxi-backed subsidiaries, securing $100 million in financing to advance a pipeline of over a dozen active programs. The company employs an asset-centric operational model, combining platforms in siRNA, targeted small molecules, photoimmunotherapy, and topical therapies to address conditions like chronic urticaria, vitiligo, atopic dermatitis, and oncology-related skin toxicities. Its lead candidate, ALY-301, has entered Phase 1/1b clinical trials.
View full company profile